Accueil   Diary - News   All news Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

 

 

Proceeds will be used to grow company’s team in Lyon and Boston, to
advance its current programs in hypoparathyroidism and severe insulin
resistance into clinical development, and to further strengthen its
product portfolio in rare endocrine and metabolic diseases

 

 

Lyon, France, July 31, 2019 - Alizé Pharma 3, a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announces that it has completed a €67 million Series A financing round. The oversubscribed Series A was led by LSP, and included Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund and Innobio 2 (managed by Bpifrance). Existing shareholders, Sham Innovation Santé/Turenne Capital, Crédit Agricole Création and TAB Consulting also participated in the financing.

 

 

Read the press release